Gonococcal susceptibility to cephalosporins--Hawaii, 2003 to 2011.
Among gonococcal isolates examined at the Hawaii State Laboratory Division from 2003 to 2011, the prevalence of elevated cefixime minimum inhibitory concentrations (MICs; ≥0.064 μg/mL) and elevated cefpodoxime MICs (≥0.19 μg/mL) increased over time. In contrast, few isolates exhibited elevated ceftriaxone MICs (≥0.094 μg/mL), and the prevalence of elevated ceftriaxone MICs did not change.
Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA. HGK9@cdc.gov
Sarah
S
Kidd
Maria V C
MV
Lee
Eloisa
E
Maningas
Alan
A
Komeya
Gail
G
Kunimoto
Norman
N
O'Connor
Alan R
AR
Katz
Glenn M
GM
Wasserman
Robert D
RD
Kirkcaldy
A Christian
AC
Whelen
D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D020682:Cefixime / Q000494:pharmacology*; D015296:Ceftizoxime / Q000031:analogs & derivatives* / Q000494:pharmacology; D002443:Ceftriaxone / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D005260:Female; D006069:Gonorrhea / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D006254:Hawaii / Q000453:epidemiology; D020010:Heterosexuality; D018451:Homosexuality, Male; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D009344:Neisseria gonorrhoeae / Q000187:drug effects* / Q000302:isolation & purification; D011159:Population Surveillance; D015995:Prevalence; D055815:Young Adult; D000097623:Cefpodoxime
D000900:Anti-Bacterial Agents; D020682:Cefixime; D015296:Ceftizoxime; D002443:Ceftriaxone; D000097623:Cefpodoxime